Why is Soleno Therapeutics facing a securities class action lawsuit?

Investors allege Soleno made misleading statements about the safety profile of its DCCR drug candidate and failed to fully disclose risks observed during its Phase 3 clinical trial.

What safety concerns are alleged in the Soleno Therapeutics lawsuit?

The complaint claims Soleno downplayed evidence of adverse effects in its Phase 3 trial, including excess fluid retention among participants.

What are investors alleging about Soleno’s disclosures?

Investors claim Soleno misrepresented or concealed safety findings, making the drug appear safer and more commercially viable than it may have been.

How can clinical trial safety issues affect a biotech company’s stock?

If new information suggests a drug may have serious side effects, investors may reassess approval prospects and revenue potential, often causing the stock to decline.

What is the deadline to seek lead plaintiff status in the Soleno lawsuit?

Investors seeking appointment as lead plaintiff must file a motion by May 5, 2026 to represent the shareholder class.

Do investors need to pay legal fees to join a securities class action?

Most securities class actions are handled on a contingency basis, meaning attorneys are typically paid only if the case results in a recovery.

How do investors receive compensation from a securities class action settlement?

If the case settles, eligible investors submit claim forms documenting their trades and may receive a portion of the settlement fund based on their losses.

What is a lead plaintiff in a securities class action?

The lead plaintiff is the investor chosen by the court to represent all class members and oversee the litigation with counsel.

What does the term “class period” mean in a securities lawsuit?

The class period is the timeframe during which the alleged misleading statements occurred and investors may have purchased the company’s stock.

What is a securities class action lawsuit?

A securities class action is a lawsuit brought on behalf of investors who claim they were harmed by misleading statements or omissions by a public company.

Soleno Therapeutics, Inc. - Faruqi & Faruqi LLP

Soleno Therapeutics, Inc.

Join Action

Case Details

Ticker SLNO

Class Period 03/26/2025 - 11/04/2025

Lead Plaintiff Deadline 05/05/2026

Days Left to Seek Plaintiff

If you are a Soleno Therapeutics investor who suffered a loss and would like to learn more, you can provide your information below:

If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (2) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by Soleno or its executives; and (3) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

Lead Plaintiff Deadline: May 5, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Soleno Therapeutics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify